Literature DB >> 27476460

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.

H Nishikawa1, H Enomoto1, Y Iwata1, K Kishino1, Y Shimono1, K Hasegawa1, C Nakano1, R Takata1, T Nishimura1, K Yoh1, A Ishii1, N Aizawa1, Y Sakai1, N Ikeda1, T Takashima1, H Iijima1, S Nishiguchi1.   

Abstract

We compared Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA+ -M2BP) levels between patients with chronic hepatitis B (n=249) and chronic hepatitis C (n=386) based on the degree of liver fibrosis. We examined WFA+ -M2BP levels in patients with F4 (cirrhosis), F3 or more (advanced fibrosis) and F2 or more (significant fibrosis) in the two groups. We further examined the relationship between five fibrosis markers and the degree of fibrosis. The WFA+ -M2BP values ranged from 0.25 cut-off index (COI) to 12.9 COI in patients with hepatitis B and 0.34-20.0 COI in patients with hepatitis C (P<.0001). The median WFA+ -M2BP values in F4 in the two groups were 2.83 COI in patients with hepatitis B and 5.03 COI in patients with hepatitis C (P=.0046). The median WFA+ -M2BP values in F3 or more in the two groups were 1.79 COI in patients with hepatitis B and 3.79 COI in patients with hepatitis C (P<.0001). The median WFA+ -M2BP values in F2 or more in the two groups were 1.49 COI in the hepatitis B cohort and 3.19 COI in the hepatitis C group (P<.0001). Among five liver fibrosis markers, WFA+ -M2BP had the highest correlation coefficient (rs =.629) in terms of correlation with the degree of fibrosis in the patients with hepatitis C and had the second highest rs value (.415) in the hepatitis B group. Although WFA+ -M2BP could be a useful indicator of liver fibrosis, WFA+ -M2BP levels in the two groups significantly differed even in the same degree of fibrosis. Individual cut-off values in each aetiology for the degree of fibrosis should be determined.
© 2016 The Authors. Journal of Viral Hepatitis Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Wisteria floribunda agglutinin-positive Mac-2-binding protein; chronic hepatitis; comparative study; liver fibrosis marker

Mesh:

Substances:

Year:  2016        PMID: 27476460     DOI: 10.1111/jvh.12575

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  16 in total

Review 1.  Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.

Authors:  Ken Shirabe; Yuki Bekki; Dolgormaa Gantumur; Kenichiro Araki; Norihiro Ishii; Atsushi Kuno; Hisashi Narimatsu; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2018-01-09       Impact factor: 7.527

2.  Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population.

Authors:  Thuy Thi Thu Pham; Dat Tan Ho; Toan Nguyen
Journal:  World J Hepatol       Date:  2020-05-27

3.  High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.

Authors:  Noboru Shinkai; Masanori Nojima; Etsuko Iio; Kayoko Matsunami; Hidenori Toyoda; Shuko Murakami; Takako Inoue; Shintaro Ogawa; Takashi Kumada; Yasuhito Tanaka
Journal:  J Gastroenterol       Date:  2017-12-29       Impact factor: 7.527

4.  Relationship between skeletal muscle mass and liver fibrosis markers for patients with hepatitis C virus related liver disease.

Authors:  Ryo Takata; Hiroki Nishikawa; Hirayuki Enomoto; Yoshinori Iwata; Akio Ishii; Yuho Miyamoto; Noriko Ishii; Yukihisa Yuri; Kunihiro Hasegawa; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

5.  Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection.

Authors:  Lung-Yi Mak; Danny Ka-Ho Wong; Ka-Shing Cheung; Wai-Kay Seto; Ching-Lung Lai; Man-Fung Yuen
Journal:  Clin Transl Gastroenterol       Date:  2018-06-19       Impact factor: 4.488

Review 6.  Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Rohit Loomba; Namiki Izumi
Journal:  Ann Lab Med       Date:  2020-08-25       Impact factor: 3.464

Review 7.  Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives.

Authors:  Ryota Masuzaki; Tatsuo Kanda; Reina Sasaki; Naoki Matsumoto; Masahiro Ogawa; Shunichi Matsuoka; Seth J Karp; Mitsuhiko Moriyama
Journal:  Int J Mol Sci       Date:  2020-07-11       Impact factor: 5.923

8.  Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy.

Authors:  Tai-Chung Tseng; Cheng-Yuan Peng; Yao-Chun Hsu; Tung-Hung Su; Chia-Chi Wang; Chun-Jen Liu; Hung-Chih Yang; Wan-Ting Yang; Chia-Hsin Lin; Ming-Lung Yu; Hsueh-Chou Lai; Yasuhito Tanaka; Mindie H Nguyen; Chen-Hua Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Liver Cancer       Date:  2020-01-10       Impact factor: 11.740

Review 9.  Novel biomarkers for the management of chronic hepatitis B.

Authors:  Takako Inoue; Yasuhito Tanaka
Journal:  Clin Mol Hepatol       Date:  2020-06-15

10.  Effect of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus on sleep disorders: a study protocol for single-arm, prospective, interventional study.

Authors:  Kazunori Yoh; Hiroki Nishikawa; Hirayuki Enomoto; Yoshinori Iwata; Akio Ishii; Yukihisa Yuri; Noriko Ishii; Yuho Miyamoto; Kunihiro Hasegawa; Chikage Nakano; Ryo Takata; Takashi Nishimura; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  BMJ Open Gastroenterol       Date:  2017-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.